Trials
2 active
6 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Atopic Dermatitis (2 trials), Atopic Dermatitis Eczema (2 trials), Eczema (2 trials)
- Main trialPhase 2
- “The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.”In the company’s words, NCT07037901 on ClinicalTrials.gov
Other drugs for Atopic Dermatitis
Coming up2
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Mar 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2027 | A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis | |
| Phase 2Enrolling by invitation | Mar 2028 | Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis | |
| Phase 1/2Terminated | 26 Apr 2024 | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) | |
| Phase 1/2Completed | 14 Jan 2025 | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants | |
| Phase 1Completed | 31 May 2023 | Evaluate IMG-007 in Healthy Participants | |
| Phase 1Terminated | 28 Aug 2024 | Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026